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AbstrAct
rationale Pulmonary non- tuberculous mycobacterial 
(PNTM) disease has increased over the past several 
decades, especially in older women. Abnormal mucociliary 
clearance and abnormal nasal nitric oxide (nNO) have 
been associated with PNTM disease in other patient 
cohorts. Mucociliary clearance can be affected by 
NO- cyclic guanosine monophosphate signalling and, 
therefore, modulation of the pathway may be possible with 
phosphodiesterase inhibitors such as sildenafil as a novel 
therapeutic approach.
Objective To define ex vivo characteristics of PNTM 
disease affected by sildenafil.
Methods Subjects with PNTM infections were 
recruited into an open- label dose- escalation trial of 
sildenafil. Laboratory measurements and mucociliary 
measurements—ciliary beat frequency, nNO and 24- hour 
sputum production—were collected throughout the study 
period. Patients received sildenafil daily during the study 
period, with escalation from 20 to 40 mg three times per 
day.
Measurements and main results Increased ciliary beat 
frequency occurred after a single dose of 40 mg sildenafil 
and after extended dosing of 40 mg sildenafil. The increase 
ciliary beat frequency was not seen with 20 mg sildenafil 
dosing. There were no changes in sputum production, nNO 
production, Quality of Life- Bronchiectasis- NTM module 
(QOL- B- NTM) questionnaire or the St George’s Respiratory 
Questionnaire during the study period.
conclusion Sildenafil, 40 mg, increased ciliary beat 
frequency acutely as well as with extended administration.
IntrOductIOn
Pulmonary non- tuberculous mycobacteria 
(PNTM) disease in otherwise healthy individ-
uals is increasing in industrialised countries 
and has been shown to have both environ-
mental and genetic associations.1–5 The clinical 
syndrome generally occurs in postmenopausal 
women, with lower body mass indices and 
without significant immunological abnormali-
ties.6 7 Familial clustering as well as high rates 
of genetic variants affecting immune, respira-
tory ciliary, cystic fibrosis transmembrane 
conductance regulator and connective tissue 
genes in patients with PNTM disease suggest a 
genetically complex aspect to the syndrome.8–10 
Patients with PNTM infections may have abnor-
malities in respiratory ciliary function and 
moderately reduced nasal nitric oxide (nNO) 
levels.11 Previous work demonstrated that the 
decreased baseline ciliary beat frequency (CBF) 
present in ex vivo PNTM patient’s respiratory 
epithelial cells could be increased through the 
ex vivo addition of phosphodiesterase V inhib-
itor, sildenafil.
Mucus clearance rates are associated with 
linear changes in CBF, and nitric oxide (NO) 
is known to be involved in regulating CBF 
through NO synthase and the activation of 
soluble guanylate cyclase leading to increased 
concentrations of cyclic guanosine mono-
phosphate (cGMP).12–14 Increases in cGMP 
concentration can also stimulate numerous 
other metabolic pathways leading to a myriad 
of effects on respiratory epithelium, as well 
Key messages
What is the key question?
 ► Is the previously identified ex vivo reduction in cil-
iary beat frequency in pulmonary non- tuberculous 
mycobacterial disease capable of being modified in 
vivo, or is the phenomena limited solely to the ex 
vivo setting?
What is the bottom line?
 ► This article describes a phase I/II study of sildenafil 
and ciliary function in patients with pulmonary non- 
tuberculous mycobacterial infections that demon-
strates sildenafil is capable of increasing ciliary beat 
frequency in vivo.
Why read on?
 ► This study describes a novel therapeutic approach or 
alternative study direction for research in the pulmo-
nary non- tuberculous mycobacterial disease.
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Figure 1 Study design: Nine patients with PNTM disease 
were enrolled. Sildenafil dosing schedule is graphically 
displayed for the clinical trial. PNTM, pulmonary non- 
tuberculous mycobacteria.
as vascular smooth muscles. The ex vivo observation that 
sildenafil leads to an increase in CBF in primary respira-
tory epithelial cells obtained from PNTM- infected patients 
led us to hypothesise that oral administration of sildenafil 
to patients with PNTM infection may result in increased 
CBF in vivo secondary to an increase in cGMP signalling. 
Considering the safety profile of sildenafil, we hypothesise 
that the augmentation of CBF could have potential benefits 
on mucociliary clearance and PNTM lung disease course; 
however, the first step was to determine if the previously 
demonstrated ex vivo effects could be replicated in vivo.
MAterIAls And MethOds
Patient recruitment
PNTM- infected patients were recruited over a 6- month 
period from March to August (2013) at the Clinical Center, 
National Institutes of Health (NIH), Bethesda, Mary-
land, USA. All patients (n=9) provided informed consent 
under an NIAID IRB- approved protocol (13- I-0075, 
NCT01853540) (figure 1) and had microbiological and 
radiographical evidence of longstanding pulmonary NTM 
infection consistent with the American Thoracic Society 
(ATS) criteria for PNTM disease.8 15 16 All study participants 
were concurrently enrolled in a longitudinal observational 
study of the Natural History, Genetics, Phenotype and 
Treatment of Mycobacterial Infections (NCT00018044), 
which allowed verification that none of the current PNTM- 
infected patients met diagnostic criteria for cystic fibrosis 
(CF) or primary ciliary dyskinesia (PCD).
study design
The study was an open- label interventional study that 
recruited subjects who were concurrently enrolled in 
a natural history protocol that examined the genetics, 
phenotype and treatment of mycobacterial infections. 
Clinical and laboratory disease status measurements were 
assessed at baseline (day 0) and on days 7 and 30. CBF 
measurements were done pre- drug and post- drug dosing 
on days 0, 7 and 30. Subjects 1–5 received a single dose of 
40 mg sildenafil on day 0 and subjects 6–9 received a single 
dose of 20 mg sildenafil on day 0. All nine subjects received 
20 mg sildenafil three times per day on days 1–7 and 40 mg 
sildenafil three times per day on days 8–30 (figure 1).
collection of respiratory epithelium
Primary human respiratory epithelial cells were collected 
as previously described.11 Primary patient epithelial 
samples were visualised at the time of collection (day of 
collection). Primary human respiratory epithelial cells 
were collected by scraping the inferior nasal turbinate 
using a Rhino- Probe (Arlington Scientific). Harvested 
nasal tissue was suspended in Dulbecco’s modified 
essential medium, high glucose, without phenol red 
(DMEM- H; Invitrogen) supplemented with gentamicin 
(50 µg/mL, Sigma), amphotericin (50 µg/mL, Sigma), 
ceftazidime (100 µg/mL, Sigma), tobramycin (80 µg/
mL, Sigma), vancomycin (100 µg/mL, Sigma), nystatin 
(100 U/mL, Sigma) and fluconazole (25 µg/mL, Sigma). 
After collection, the respiratory epithelial cells were 
resuspended in a hormonally supplemented respiratory 
epithelial cell medium (Lonza, Walkersvile, Maryland, 
USA) and keep at 37°C until imaging.
Analysis of cbF
The time interval between the harvest of respiratory 
epithelial cells and the measurement of CBF was between 
60 and 180 min. Cells and cilia were visualised using 
transmitted light in bright- field mode with a 63× (NA 1.3) 
glycerol objective on a Leica DM IRBE inverted scope 
(Leica Microsystems) on a vibration dampened table. 
Images and videos were captured using a Model A602f-2 
Basler area scan high- speed monochromatic digital video 
camera (Basler AG) at a sampling rate of 100 frames/s 
with a resolution of 640×480 pixels. The images were 
analysed using the Sisson- Ammons Video Analysis (SAVA) 
system V.2.1.15 (Ammons Engineering). All imaging was 
done at 37°C. Temperature and humidity conditions 
were maintained through the use of a heated insert, S-2 
incubator chamber and objective heater (PeCon). For 
each respiratory epithelial sample, 20 different field views 
were continuously recorded for 2.5 s at 100 frames/s. 
The videos and images were compressed and stored for 
later analysis. CBF of the de- identified videos was deter-
mined by region of interest (ROI) analysis in which CBF 
was determined by the SAVA software system (Ammons 
Engineering, Michigan, USA).17 ROI was independently 
determined by two blinded investigators on the de- iden-
tified videos. Multiple videos and ROI were analysed for 
each time point. The CBF between the two investigators 
were then averaged for a final CBF per time point.
Measurement of nasal airway nO
nNO was measured in concordance with ATS guidelines 
by direct sampling through a NO analyser (model 280i, 
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Table 1 Population characteristics and bacterial organisms
 
Characteristics
Patients with PNTM 
disease (N=9)
Mean age, mean±SD (years) 63±8
Female gender, n (%) 9 (100)
Ethnicity
  White, n (%) 9 (100)
Never smokers, n (%) 3 (33)
CFTR carriers, n (%) 2 (22)
Scoliosis, n (%) 3 (33)
Joint hypermobility, n (%) 2 (22)
Positive thumb- wrist sign, n (%) 1 (11)
Mitral valve prolapse, n (%) 0 (0)
Cough, n (%) 9 (100)
Bronchiectasis, n (%) 9 (100)
Previous history of NTM- positive sputum, 
n (%)
9 (100)
On NTM therapy at collection, n (%) 5 (56)
Elevated inflammatory markers at 
collection, n (%)
5 (56)
Macrolide exposure at collection, n (%) 4 (44)
Immunomodulatory drugs, n % 0 (0)
BMI, mean±SD 20.8±3.2
Mycobacteria, n (%)
  MAC 4 (45)
  MAB 3 (33)
  MAC & MAB 2 (22)
BMI, body mass index; CFTR, cystic fibrosis transmembrane 
conductance regulator; MAB, mycobacterium abscessus; MAC, 
mycobacterium avium complex; NTM, non- tuberculous mycobacteria.
Sievers Instrument, Boulder, Colorado, USA) and reported 
as steady- state production of NO in nL/minute.18
sputum collection and measurement
Twenty- four- hour sputum collections were performed 
and weights recorded at days 0, 7 and 30 as previously 
described.19
Questionnaires
Self- administered quality of life and functional ques-
tionnaires were administered throughout the study 
period. The Quality of Life- Bronchiectasis- NTM module 
(QOL- B- NTM) questionnaire quantifies disease- specific 
symptom severity and quality of life and was performed 
as previously described at baseline, day 7 and day 30.20 
The St. George’s Respiratory Questionnaire (SGRQ) 
evaluates the health- related quality of life in subjects with 
the chronic pulmonary disease with a 30- day recall. The 
SGRQ was performed at baseline, day 30 and day 45.21
Patient and public involvement
Patient care at the Clinical Centre, NIH, is performed 
as part of clinical studies. Patients and the public are 
involved during study design as part of the NIAID IRB 
approval process. There was no patient involvement in 
the recruitment and conduct of the study. Patients were 
not invited to contribute to the writing.
statistical analysis
Data, including figures, are expressed as mean±SD, statis-
tical testing was done using the two- tailed Student t- test 
with Welch’s correction and one- way analysis of variance 
(ANOVA) with Dunnett correction.
results
demographics
Nine patients with PNTM disease were enrolled, age 
63±8 years (range: 58 to 80 years); all were Caucasian 
women. The mean body mass index was 20.8±3.2 kg/
m2. All patients reported chronic cough and had radio-
graphically demonstrated bronchiectasis prior to enrol-
ment. Sixty- six per cent (n=6) reported haemoptysis 
and 44% reported sinusitis, but only one had a history 
of otitis media. Thirty- three per cent (n=3) reported a 
remote history of smoking. Twenty- two per cent (n=2) 
had joint hypermobility (Beighton Hypermobility score), 
11% (n=1) a positive thumb- wrist sign (self- reported)22 
and none had echocardiography- proven mitral valve 
prolapse. The mean forced expiratory volume in 1 s (% 
predicted) was 85%±24%. Mutations in cystic fibrosis-
transmembrane conductance regulator, determined by 
full gene sequence (Ambry Genetics, Aliso Viejo, Cali-
fornia, USA), were absent in 33% (n=3), present on a 
single allele in 22% (n=2) and unknown in 44% (n=4). At 
the time of respiratory epithelial collection, 56% (n=5) 
were on NTM- associated medications (clarithromycin, 
azithromycin, rifampin, rifabutin, rifapentine, etham-
butol, amikacin, isoniazid, imipenem, meropenem, tige-
cycline, cefoxitin, linezolid, clofazimine or moxifloxacin) 
and all had positive NTM cultures. NTM was isolated 
from all the patients at some time prior to enrolment: 
45% (n=4) of the patients had mycobacterium avium 
complex (MAC), 33% (n=3) mycobacterium abscessus 
(MAB), and 22% (n=2) had both MAC and MAB. Fifty- six 
per cent had elevated C reactive protein test or beta-2 
microglobulin at the time of consent (table 1).
Adverse events
There were no serious adverse events, adverse events leading 
to treatment discontinuation or death noted in the study. 
All adverse events during the study were grade ≤2. Adverse 
events in patients associated with study drug included: 44% 
(n=4) headache that spontaneously resolved within 15 min 
of study drug, and 22% (n=2) nasal congestion. Adverse 
events occurring in more than one study patient included: 
22% (n=2) decreased serum albumin, 22% (n=2) hypo-
magnesaemia, 22% (n=2) lymphopenia and 22% (n=2) 
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Figure 3 nNO and sputum production in study patients 
with PNTM disease. (A) Individual nNO in patients with 
PNTM disease (n=9), done predosing at days 0, 7 and 30. 
there was no significant trend in nNO throughout the study. 
(B) Mean nNO for patients with PNTM disease. at baseline, 
nNO was 232±61 nL/min, similar to previous results. nNO 
for historical PNTM controls11 represented by greyed zone 
on the y- axis (data are presented as means, error bars 
show SD). (C) Individual 24- hour sputum weights in patients 
with PNTM disease (n=9) at days 0, 7 and 30 of the study. 
No significant trends were noted in the amount of sputum 
produced over the course of the study. nNO, nasal nitric 
oxide; PNTM, pulmonary non- tuberculous mycobacteria.
Figure 2 CBF response to sildenafil: (A) Absolute CBF 
on day 0 for patients with PNTM disease prior and 2 hours 
post a single dose of either 20 mg sildenafil (n=3) or 
40 mg sildenafil (n=5). Patients with PNTM disease had a 
mean CBF of 8.96±1.2 Hz, with no significant difference 
between the two groups prior to sildenafil dose. The 
40 mg sildenafil group’s CBF was significantly elevated to 
10.79±0.6 Hz (p<0.008, two- tailed t- test) post sildenafil. 
(B) Mean absolute CBF at days 0, 7 and 30 (n=9). CBF 
measurement was done at prior to sildenafil at day 0. 
CBF was measured prior to and post the 20 mg dose of 
sildenafil at the end of 1 week (day 7 pre- time and post- time 
point) and prior to and post the 40 mg dose of sildenafil 
at 4 weeks (day 30 pre- time and post- time point). CBF at 
the day 30 post sildenafil dose was significantly elevated 
to 10.73±1.2 Hz compared with day 0 predose (p<0.004, 
ANOVA with Dunnett correction). CBF for historical healthy 
controls11 represented by greyed zone on the y- axis (data 
are presented as means, error bars show SD, **p<0.01). 
ANOVA, analysis of variance; CBF, ciliary beat frequency; 
PNTM, pulmonary non- tuberculous mycobacteria.
thrombocytopenia (n=2). No other adverse event occurred 
in more than one patient.
Immediate effects of in vivo addition of sildenafil on cbF
To determine if CBF in PNTM patient respiratory epithe-
lium could be increased by in vivo inhibition of phosphodi-
esterase V with sildenafil, patients were administered either 
a single dose of 20 mg sildenafil (n=4) or 40 mg sildenafil 
(n=5). One patient in the 20 mg sildenafil cohort specimen 
was unable to have samples successfully processed post 
sildenafil dosing. CBF was measured before the oral dosing 
and 2 hours after the oral dosing of sildenafil. Prior to 
sildenafil dosing, patients with PNTM disease had a mean 
CBF of 8.96±1.2 Hz, with no significant difference between 
the two groups, similar to our previous data.11 Two hours 
after sildenafil dosing, the 40 mg sildenafil group’s CBF was 
significantly elevated to 10.79±0.6 Hz (figure 2A) (p<0.008 
two- tailed t- test). In contrast, the 20 mg sildenafil group’s 
CBF was not significantly different from baseline.
temporal effects of in vivo addition of sildenafil on cbF
To determine whether the increase in CBF in PNTM 
patient respiratory epithelium was maintained with 
prolonged dosing of sildenafil, all nine patients with 
PNTM disease were dosed with 20 mg sildenafil three 
times per day for 1 week followed by 40 mg sildenafil 
three times per day for 3 weeks. Measurement of CBF was 
done before and after the 20 mg dose of sildenafil at day 
7 and before and after the 40 mg dose of sildenafil at day 
30. The CBF in the patient with PNTM disease respira-
tory epithelium was significantly elevated to 10.73±1.2 Hz 
after 40 mg sildenafil on day 30 (figure 2B) (p<0.004, 
ANOVA).
effects of in vivo addition of sildenafil on nnO
Patients with PNTM disease have been previously shown 
to have moderately reduced nNO levels in vivo. The 
patients with PNTM disease enrolled in the clinical trial 
had a mean nNO level of 232±61 nL/min at the time of 
consent. There was no significant change in the average 
nNO throughout the trial (figure 3A,B).
effects of in vivo addition of sildenafil on sputum production
We measured sputum weight over time in patients with 
PNTM disease, as enhanced ciliary clearance might be 
expected to alter sputum production. Previous research 
has demonstrated that patients with PNTM disease have 
variable sputum production.4 The 24- hour sputum 
weights before and during exposure to study the drug 
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Figure 4 Self- administered questionnaires (QOL- B- NTM 
and SGRQ) in patients with PNTM disease. (A) The QOL- 
B- NTM questionnaire (n=9) was performed at baseline, day 
7 and day 30. We found no significant trends in frequency 
symptoms. (B) The QOL- B- NTM questionnaire (n=9) 
was performed at baseline, day 7, day 30. we found no 
significant trends in severity of symptoms. (C) The QOL- B- 
NTM questionnaire (n=9) was performed at baseline, day 
7 and day 30. We found no significant changes in physical 
symptoms. (D) The SGRQ was performed at baseline, 
day 30 and day 45. We found no significant trends in the 
SGRQ over the course of the study (data are presented 
as means, error bars show SD). PNTM, pulmonary non- 
tuberculousmycobacteria; QOL- B- NTM, Quality of Life- 
Bronchiectasis- Non- TuberculousMycobacterial; SGRQ, St. 
George’s Respiratory Questionnaire.
showed no significant trend during the study period 
(figure 3C).
self-administered questionnaires
Self- administered quality of life and functional ques-
tionnaires were completed throughout the study 
period. We found no significant changes in the reports 
of symptoms on the QOL- B- NTM during the course of 
the clinical trial (figure 4A–C). Similarly, we found no 
significant trends in the SGRQ over the course of the 
study (figure 4D).
dIscussIOn
NO donors have been previously shown to rapidly 
increase mucociliary activity ex vivo.23 We have previ-
ously shown that patients with PNTM infection have 
decreased nNO and their respiratory epithelial cells’ 
CBF is reduced when compared with healthy controls 
or other respiratory disease states.11 We have also 
recently shown that mycobacterial infection of respira-
tory epithelial cells reduces the expression of ciliary- 
related genes.24 Therefore, we hypothesised that modu-
lation of the NO- cGMP pathway might be attractive in 
this patient population, even though the precise role of 
mucociliary clearance in PNTM infection is undefined.
Sildenafil increases intracellular concentrations of 
cGMP through the inhibition of phosphodiesterase V, 
which affects the NO- cGMP pathway. The modulation 
of cGMP by sildenafil has been extensively studied in 
the cardiovascular system,25 as well as in the treatment 
of pulmonary arterial hypertension.26 It has also been 
studied as a therapy for patients with chronic obstruc-
tive pulmonary disease.26
We found a significant increase in ex vivo CBF with 
a single oral dose of 40 mg of sildenafil (figure 2A), 
which was not seen with the 20 mg dose. Prolonged 
dosing of sildenafil noted a significant increase in CBF 
only after the final dose of sildenafil 40 mg (figure 2B), 
suggesting that continued dosing of sildenafil did not 
lead to tachyphylaxis or downregulation of the effect 
of sildenafil on the NO- cGMP pathway. The absence 
of sustained response and the non- significance of the 
predose sample collection at day 30 could be due to the 
timing of the last dose of sildenafil. The terminal half- 
life of sildenafil is approximately 4 hours.27 The day 29 
previous dose of sildenafil would have been >10 hours 
prior to sample collection.
No significant increase in nNO in PNTM- infected 
patients treated with sildenafil was noted (figure 3A,B). 
This was consistent with our previous demonstration of 
the absence of a linear correlation between CBF and 
nNO levels. It is interesting to note the trend toward 
increased nNO at treatment day 30, which corresponds 
to the increased CBF seen with higher sildenafil dosing 
(figure 3B). Sputum production was quite variable 
throughout the study period (figure 3C), possibly 
secondary to the difficulty of adequately measuring 
sputum production while accounting for saliva produc-
tion and the small sample size of the study.
Patient- reported outcomes of physical function, 
emotional state and social interactions are important 
in a chronic disease such as PNTM infection and are 
likely to be important markers in the development 
of new therapies. Patients with PNTM infection have 
decreased health- related quality of life compared 
with healthy controls.28 29 The QOL- B- NTM question-
naire20 showed no significant difference during the 
study period in frequency, severity of disease- specific 
symptoms or physical impact of the disease (figure 4). 
SGRQ detected a clinical reduction in symptoms, but 
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it was not significant (figure 4D). The dosing and/or 
the time course of the study could be too short to note 
changes in patient- reported clinical outcomes. Enroll-
ment of patients with well- established PNTM disease 
can provide a cohort with a well- defined disease state, 
but the chronic infection stage may not be an optimal 
period for intervention with this type of therapy. The 
patient- reported measures were included in the study 
as secondary outcomes to assess feasibility, as well as 
to assist with future study directions. Importantly, 
sildenafil did not appear to worsen any patient’s self- 
reported outcomes.
cOnclusIOns
The abnormality in CBF in PNTM infection that we have 
identified is modest, aligning with the fact that most 
aspects of life are relatively normal in patients with PNTM 
infection until the fifth or sixth decades. The abnormal-
ities in the NO- cGMP pathway seen previously ex vivo in 
patients with PNTM disease are measurable and modi-
fiable in vivo with sildenafil. This novel therapy has a 
strong safety record and appears to have minimal adverse 
events. Although further studies will be necessary to assess 
the potential effect of modulating the NO- cGMP pathway 
in the disease course of patients with PNTM infection, 
this class of medication may offer a novel therapeutic 
approach or alternative study direction for research in 
patients with PNTM infection.
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